谭敏佳 Minjia Tan

研究工作围绕基于蛋白组学技术的蛋白修饰调控和药物精准干预开展研究。研究工作发现了蛋白翻译后修饰在表观遗传和细胞代谢调控中的新机制，揭示了靶向干预蛋白修饰在疾病治疗中的重要性和普遍性，为相关肿瘤和代谢性疾病的机理和精准治疗新策略研究奠定重要基础。共发表SCI论文120余篇，总引用率1.3万余次，其中近五年以通讯作者（含共同）发表在Cell (2018, 2020)、Cell Metab (2021)、Mol Cell (2021, 2022)、Nat Chem (2023)、Sci Transl Med (2024)、Nat Commun (2018, 2024)、J Am Chem Soc (2023)等知名国际学术期刊，研究工作入选《中国2020年度重要医学进展》。荣获国家杰出青年科学基金、中国青年科技奖、国家特支计划科技创新领军人才、科技部中青年科技创新领军人才、国家海外高层次青年人才计划、教育部高校自然科学奖一等奖、上海青年科技英才（基础研究类）、药明康德生命化学学者奖、中源协和生命医学创新突破奖、上海市优秀学术带头人、中科院上海分院杰出青年科技创新人才、上海市浦江人才、中国人类蛋白质组学会优秀青年学者奖等荣誉。

Research work focuses on protein modification regulation and precision drug intervention based on proteomics technology. The research has discovered new mechanisms of post-translational modifications in epigenetics and cellular metabolism regulation, revealed the importance and universality of targeted intervention of protein modifications in disease treatment, and laid an important foundation for research on mechanisms and new precision treatment strategies for related tumors and metabolic diseases. Has published over 120 SCI papers with more than 13,000 total citations. In the past five years, has published as corresponding author (including co-corresponding) in well-known international academic journals such as Cell (2018, 2020), Cell Metab (2021), Mol Cell (2021, 2022), Nat Chem (2023), Sci Transl Med (2024), Nat Commun (2018, 2024), and J Am Chem Soc (2023). Research work was selected for “Important Medical Progress in China in 2020”. Has received honors including National Science Fund for Distinguished Young Scholars, Chinese Youth Science and Technology Award, National Special Support Plan for Leading Talents in Science and Technology Innovation, Ministry of Science and Technology Leading Talents in Science and Technology Innovation for Young and Middle-aged, National Overseas High-level Youth Talent Program, First Prize of Ministry of Education Natural Science Award for Higher Education Institutions, Shanghai Young Science and Technology Talent (Basic Research Category), WuXi AppTec Life Chemistry Scholar Award, China Stem Cell Innovation Breakthrough Award in Life Medicine, Shanghai Outstanding Academic Leader, Shanghai Branch of Chinese Academy of Sciences Outstanding Young Science and Technology Innovation Talent, Shanghai Pujiang Talent, and Chinese Human Proteome Organization Excellent Young Scholar Award.

1. Liu Z, Liu Y, Qian L, Jiang S, Gai X, Ye S, Chen Y, Wang X, Zhai L, Xu J, Pu C, Li J, He F, Huang M*, and Tan M*. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Mol Cell, 2021, 81: 4076-4090
2. Xu J, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, Qian K, Sun C, Liu Z, Jiang S, Wang M, Feng L, Zhao L, Liu P, Wang B, Zhao X, Xie H, Yang X, Zhao L, Chang Y, Jia J, Wang X, Zhang Y, Wang Y, Yang Y, Wu Z, Yang L, Liu B, Zhao T, Ren S, Sun A, Zhao Y, Ying W, Wang F, Wang G, Zhang Y, Cheng S, Qin J, Qian X, Wang Y, Li J, He F, Xiao T, Tan M*. Integrative proteomic characterization of human lung adenocarcinoma. 2020 Cell 182: 245-261